Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-61393215 healthy volunteer PK and safety study
NL-OMON46054Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of rocavorexant in anxiety disorder and affective disorder (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Pharmacokinetics, safety, and tolerability after single ascending oral doses, Relative bioavailability of capsule versus suspension and 2 more. Started Sep 2018; status: completed.
02
Drugs
rocavorexant
03
Conditions
anxiety disorderaffective disorder
Beyond the preview
Go deeper on NL-OMON46054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46054.